drugset / Trial / NCT02182557

WAL 801 CL Dry Syrup in Paediatric Atopic Dermatitis Patients

NCT02182557

Phase 3 Completed 162 enrolled Boehringer Ingelheim
RandomizedParallel-groupDouble-blindTreatment

Summary

Study to investigate the safety and efficacy of WAL 801 CL Dry Syrup on pruritus associated with paediatric atopic dermatitis in comparison with that of Ketotifen Fumarate Dry Syrup and to confirm the appropriateness of dosage of WAL801 Dry Syrup.

Timeline

Start
2001-06
Primary completion
2002-01
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Epinastine Small molecule
Comparator Ketotifen Small molecule

Indications